Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBIO 
Mustang Bio Inc (MBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.91% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.44M USD | Price to earnings Ratio 0.79 | 1Y Target Price 10 |
Price to earnings Ratio 0.79 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 2.23 | 52 Weeks Range 0.95 - 18.50 | Updated Date 09/16/2025 |
52 Weeks Range 0.95 - 18.50 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.89% | Return on Equity (TTM) -1191.31% |
Valuation
Trailing PE 0.79 | Forward PE - | Enterprise Value -1218360 | Price to Sales(TTM) - |
Enterprise Value -1218360 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 6394260 | Shares Floating 6192539 |
Shares Outstanding 6394260 | Shares Floating 6192539 | ||
Percent Insiders 3.16 | Percent Institutions 3.18 |
Upturn AI SWOT
Mustang Bio Inc
Company Overview
History and Background
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Founded in 2015, it licenses technology from institutions like City of Hope and Fred Hutchinson Cancer Research Center.
Core Business Areas
- Cell Therapy: Developing cell therapies for hematologic malignancies and solid tumors, utilizing CAR-T cell technology and other approaches.
- Gene Therapy: Focusing on gene therapy for rare genetic diseases.
Leadership and Structure
Manuel Litchman, M.D., Ph.D. is the President and Chief Executive Officer. The company has a typical biopharmaceutical organizational structure with departments focused on research, clinical development, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- MB-106 (CD20-targeted CAR-T cell therapy): MB-106 is being developed for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL). There is no current market share data, as it's in clinical trials. Competitors include Kite Pharma (Gilead), Novartis and Bristol Myers Squibb.
- MB-107 (onco-HSV): MB-107, an oncolytic virus for the treatment of recurrent glioblastoma. Currently in early phase studies. Competitors include DNAtrix, Tocagen (acquired by Forte Biosciences).
- MB-207 (gene therapy for X-linked severe combined immunodeficiency (XSCID)): MB-207 aims to use retroviral gene therapy to treat patients with XSCID, a rare genetic disease. No current market share data, as it is in clinical trials. Competitors include Orchard Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly cell and gene therapy, is experiencing rapid growth and innovation. Demand for novel cancer therapies and treatments for rare genetic diseases is high.
Positioning
Mustang Bio is a relatively small player focusing on niche areas within cell and gene therapy. Their strategy is to in-license promising technologies and advance them through clinical development. Their competitive advantage is tied to the specific targets of their therapies and their collaboration with renowned research institutions.
Total Addressable Market (TAM)
The TAM for cell and gene therapies is estimated to reach billions of dollars within the next decade. Mustang Bio's specific TAM depends on the successful commercialization of their pipeline assets. They are positioned to address unmet needs in specific hematologic cancers, solid tumors, and rare genetic diseases.
Upturn SWOT Analysis
Strengths
- In-licensing strategy provides access to innovative technologies
- Collaboration with leading research institutions
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- High clinical trial risk
- Reliance on third-party manufacturing for some products
- Dependent on successful regulatory approvals
Opportunities
- Positive clinical trial results could significantly increase company value
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Orphan drug designation for rare diseases
Threats
- Clinical trial failures
- Competition from other cell and gene therapy companies
- Regulatory hurdles
- Manufacturing challenges
- Patent disputes
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
Mustang Bio competes with larger pharmaceutical companies with greater resources. Their success depends on demonstrating superior efficacy and safety with their therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to advancing pipeline candidates through clinical trials. Stock performance has fluctuated based on news related to clinical data releases.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates will vary widely.
Recent Initiatives: Focusing on advancing key pipeline candidates, securing additional funding, and strengthening manufacturing capabilities.
Summary
Mustang Bio is a clinical-stage biopharmaceutical firm specializing in cell and gene therapies with a focus on hematologic cancers, solid tumors, and rare diseases. They utilize an in-licensing strategy to access innovative technologies from leading research institutions. Key opportunities revolve around positive clinical trial results and partnerships. Challenges include limited finances, clinical risks, and regulatory hurdles. Overall, Mustang Bio is a high-risk, high-reward investment tied to the success of its clinical pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Investing in biopharmaceutical companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mustang Bio Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2017-08-22 | President, CEO, Interim CFO & Director Dr. Manuel Litchman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.mustangbio.com |
Full time employees 6 | Website https://www.mustangbio.com | ||
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.